Key facts
- myBiometry’s last known valuation is $31.5M (Dec 2025).
- It has raised $15.8M; the latest was Accelerator/Incubator ($50K) in Feb 2026.
- Notable investors include MassChallenge, MedTech Innovator, Matter (Consulting Services (B2B)), Elevate Ventures, New York Angels — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for myBiometry
- ·The full record, as it builds
Funding rounds
No funding rounds for myBiometry are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About myBiometry
Developer of a remote-monitoring platform designed for respiratory disease management. The company's platform uses a patented sensor and breath-based biomarker measurement together with software that aggregates clinical and environmental risk factors to assess airway inflammation and predict exacerbation risk in advance, enabling healthcare providers and patients to monitor chronic respiratory conditions and receive actionable biological data for disease management and prevention.
- Sector
- Healthcare
- HQ
- Lowell, MA, United States
- Founded
- 2013
- Employees
- 9
- Website
- mybiometry.com/
- Ownership
- Privately Held (backing)
myBiometry doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in myBiometry shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on myBiometry in its N-PORT filings yet. We sweep new filings monthly.